PMHS Polomar Health Services, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1265521 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11,701.9%
TTM net income YoY-303.9%
TTM EPS YoY-300.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin49.1%
Operating margin-221.0%
Net margin-224.6%
FCF margin—
EBITDA margin-14.8%
Returns
ROE-469.6%
ROA-193.3%
ROIC (approx.)-392.6%
Asset turnover0.86x
Leverage & solvency
Liabilities / assets325.5%
Debt / equity—
Current ratio0.24x
Interest coverage-61.19x
Cash quality & payout
Operating cash flow / net income-0.04x
Accruals ratio-200.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $648,231 | $58,824 |
| Cost of revenue | $188,132 | $27,921 |
| Gross profit | $460,099 | $30,903 |
| SG&A expense | $10.94M | $1.28M |
| Operating income | -$10.55M | -$1.30M |
| Interest expense | $150,841 | $41,837 |
| Net income | -$10.70M | -$1.34M |
| EBITDA | -$776,936 | -$1.04M |
| EPS (basic) | -0.39 | -0.05 |
| EPS (diluted) | -0.39 | -0.05 |
| Weighted avg. shares (diluted) | 27.76M | 27.66M |
| Balance sheet | ||
| Cash & equivalents | $132,150 | $6,191 |
| Inventory | $93,636 | $68,777 |
| Current assets | $322,727 | $76,813 |
| PP&E, net | $43,452 | $81,405 |
| Total assets | $390,043 | $9.95M |
| Current liabilities | $1.61M | $1.34M |
| Total liabilities | $1.61M | $1.35M |
| Shareholders' equity | -$1.97M | $8.60M |
| Shares outstanding | 28.02M | 27.66M |
| Cash flow statement | ||
| Operating cash flow | -$395,995 | -$1.02M |
| Capital expenditure | — | $90,893 |
| Free cash flow | — | -$1.11M |
| Investing cash flow | — | -$90,893 |
| Financing cash flow | $521,954 | $1.11M |
| Depreciation & amortization | $9.77M | $263,280 |
| Stock-based compensation | $129,645 | — |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.